Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biohaven Pharmaceuticals
Biotech
Biohaven's biopolar med fails pivotal test
BHV-7000 is currently being evaluated in three other phase 2/3 studies across major depressive disorder, focal epilepsy and generalized epilepsy.
Gabrielle Masson
Mar 3, 2025 5:14pm
Biohaven fails phase 3 SMA test but plans talks with FDA
Nov 25, 2024 9:56am
Biohaven bounces back with phase 3 ultra-rare disease win
Sep 23, 2024 9:22am
Immunovant promotes next-gen FcRn drug in race to rival Vyvgart
May 30, 2024 7:02am
Pfizer's migraine market chief joins Apnimed—Chutes & Ladders
Jan 26, 2024 9:30am
A blow for Biohaven as FDA refuses failed rare disease drug
Jul 27, 2023 9:41am
